Second edition — Nov 8–10, 2027 — Baltimore, MD Abstract submission — Oct 12, 2026 Registration — Nov 01, 2026

Scientific committee

§01
Khosrow Kashfi, PhD, FRSC, FRSB
Khosrow Kashfi, PhD, FRSC, FRSB
CUNY School of Medicine · New York, NY

Associate medical professor of biochemistry and pharmacology. His laboratory develops nitric oxide- and hydrogen sulfide-releasing compounds (NOSH-NSAIDs) for the prevention and treatment of colon, pancreatic, and ER-negative breast cancers.

Geeta Upadhyay, PhD
Geeta Upadhyay, PhD
Uniformed Services University · Bethesda, MD

Associate professor in the Departments of Pathology and Molecular & Cellular Biology. Her lab studies the Ly6 gene family in TGF-β signaling and immune escape, with a focus on triple-negative breast cancer and targeted therapy resistance.

Lucas Ferrari de Andrade, PhD
Lucas Ferrari de Andrade, PhD
Icahn School of Medicine at Mount Sinai · New York, NY

Associate professor in the Department of Immunology and Immunotherapy and the Precision Immunology Institute. His laboratory develops pharmacological approaches to promote natural killer (NK) cell-mediated immunity against solid tumors and hematologic malignancies.

Suresh Ambudkar, PhD
Suresh Ambudkar, PhD
National Cancer Institute / NIH · Bethesda, MD

Senior investigator studying ATP-binding cassette (ABC) drug transporters, including P-glycoprotein, and their role in multidrug resistance — with the goal of developing strategies to restore chemotherapy sensitivity.

William Gmeiner, PhD, MBA
William Gmeiner, PhD, MBA
Wake Forest University School of Medicine · Winston-Salem, NC

Professor of cancer biology whose lab studies the mechanisms by which anticancer drugs induce cell death, and designs new nucleic-acid-based therapeutics, including a novel fluoropyrimidine polymer platform.

Lee Graves, PhD
Lee Graves, PhD
University of North Carolina at Chapel Hill · Chapel Hill, NC

Professor of pharmacology researching cellular mechanisms of drug resistance in cancer, using kinome-wide proteomics to understand how cancer cells respond and adapt to targeted therapies.